leisure time -WSS

leisure time

author：hotspot 2025-09-30 01:13:51 - browse：18

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： Why some fertility treatments produce more boy babies

WSS

A new approach to psychiatric drug development

Hospitals need to get ahead of regulations on climate change

For AI in health care standards, federal regulators join with industry group

U.S. death rates show how politics are affecting public health

Microsoft's Peter Lee: Generative AI could help doctors be more human

Decentralized clinical trials need collaboration to achieve wider use

leisure time

leisure time

knowledge

In age of alternative facts, a scholarly course on calling out crap

Hospitals need to get ahead of regulations on climate change

Tori Bowie and the unacceptable rates of Black maternal death

J&J reports mixed data on next

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Medical students need to learn the potent medicine of empathy

Jerome Adams on the need for new antivirals for Covid

Medicare drug price negotiation continues, as pharma counteroffers

Moonlake's readout produced a cash windfall. Risks remain

The Bio Revolution is changing business and society

hotspot

Lack of health data on LGBTQ+ people has serious consequences

Why some fertility treatments produce more boy babies

Medicare drug price negotiation continues, as pharma counteroffers

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

Biden's 'march

Change Healthcare cyberattack affects 25% of CVS/Aetna insurance claims

explore

entertainment

hotspot

Wikipedia